Anyouping (finotonlimab)

P2, N=116, Not yet recruiting, Eye & ENT Hospital of Fudan University

P2, N=84, Not yet recruiting, Jiangxi cancer hospital; Jiangxi cancer hospital

From the perspective of the Chinese population, finotonlimab-chemotherapy is the most cost-effective first-line treatment for R/M HNSCC, followed by cetuximab-chemotherapy. Pembrolizumab, whether as monotherapy or in combination, does not offer economic benefits.

Immunotherapy has demonstrated limited efficacy against microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Oxaliplatin may induce greater immune activation, with GZMA and CXCL13 serving as potential prognostic biomarkers. Thus, combining immunotherapy, EGFR inhibitors, and XELOX represents an optimal therapeutic strategy for mCRC.

P1, N=10, Not yet recruiting, Bejing Tongren Hospital, Capital Medical Uniersity; Bejing Tongren Hospital, Capital Medical Uniersity

P1, N=10, Not yet recruiting, Beijing Tongren Hospital

P=N/A, N=130, Active, not recruiting, Tongji Hospital

P4, N=300, Not yet recruiting, Shanghai East Hospital; Shanghai East Hospital

P3, N=188, Terminated, Sinocelltech Ltd. | N=360 --> 188 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Feb 2023; Strategy adjustments, independent of the safety and efficacy of the trial medication

P2/3, N=405, Active, not recruiting, Sinocelltech Ltd. | Recruiting --> Active, not recruiting

SCT200 combined with SCT-I10A demonstrated promising efficacy in previously treated RAS/BRAF wt mCRC patients with an acceptable safety profile. Further head-to-head studies with larger sample sizes are needed to validate whether the efficacy and safety of combined anti-EGFR and anti-PD-1 therapy are superior to anti-EGFR monotherapy in the third-line setting. (Registration No. NCT04229537).

P1, N=120, Recruiting, Sinocelltech Ltd.